2. Signaling Pathways
  3. Apoptosis
  4. Ferroptosis

Ferroptosis

Ferroptosis

Ferroptosis

Related Products

PDF 0.68 MB

Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc− (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.

Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-173600
    CYCS-INPP4A PPI-IN-1
    		Inducer 99.97%
    CYCS-INPP4A interaction-IN-1 (10A3) disrupts the CYCS-INPP4A interaction complex and enhances ferroptosis-mediated tumor suppression.
    CYCS-INPP4A PPI-IN-1
  • HY-161388
    NSCLC-IN-1
    		Inducer
    NSCLC-IN-1 (Compound A10-2) induces mitophagy and ferroptosis through targeting transmembrane BAX inhibitor motif containing 6 (TMBIM6). NSCLC-IN-1 induces mitochondrial Ca2+ imbalance, leading to mitochondrial damage. NSCLC-IN-1 reduces intracellular glutathione (GSH), increases the accumulation of lipid peroxides (LPO) and malondialdehyde (MDA) content. NSCLC-IN-1 is a potent anti-NSCLC agent.
    NSCLC-IN-1
  • HY-50898S2
    Lapatinib-d5
    		Activator
    Lapatinib-d5 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib-d<sub>5</sub>
  • HY-182055
    Anticancer agent 309
    		Activator
    Anticancer agent 309 (Compound HZ-1) is an anticancer agent and G-quadruplex binder, with Kd values of 2.46 μM and 1.61 μM for c-Myc G4 and KRAS G4, respectively. Anticancer agent 309 promotes the formation of intranuclear G4. Anticancer agent 309 shows higher selectivity for parallel G4 than for non-parallel G4. Anticancer agent 309 inhibits the NRF2 signaling pathway and reduces the expression of XCT and GPX4. Anticancer agent 309 induces Ferroptosis, Apoptosis and immunogenic cell death in cells. Anticancer agent 309 exerts antitumor efficacy against breast cancer. Anticancer agent 309 is applicable for the research of breast cancer.
    Anticancer agent 309
  • HY-178997
    NFE2L1 activator-1
    		Inhibitor
    NFE2L1 activator-1 (Compound 5b) is a potent nuclear factor erythroid 2-related factor 1 (NFE2L1) activator (EC50 = 2.4 µM). NFE2L1 activator-1 effectively resists ferroptosis (Ferroptosis). NFE2L1 activator-1 can specifically activate the NFE2L1 signaling pathway to upregulate GPX4, PSMB7, PSMC4. NFE2L1 activator-1 can be used in cancer research.
    NFE2L1 activator-1
  • HY-B0215S1
    Acetylcysteine-15N
    		Inhibitor
    Acetylcysteine-15N (N-Acetylcysteine-15N) is the 15N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies.
    Acetylcysteine-<sup>15</sup>N
  • HY-161647
    Antitumor agent-156
    		Inducer
    Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability.
    Antitumor agent-156
  • HY-B0094S3
    Artemisinin-13C,d4
    		Activator
    Artemisinin-13C,d4 is 13C and deuterated labeled Artemisinin (HY-B0094). Artemisinin (Qinghaosu), a sesquiterpene lactone, is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects.
    Artemisinin-<sup>13</sup>C,d<sub>4</sub>
  • HY-184173
    OXPHOS-IN-3
    		Inhibitor
    OXPHOS-IN-3 is a mitochondria-targeted dual OXPHOS/glycolysis inhibitor. OXPHOS-IN-3 exhibits potent antiproliferative activity against pancreatic cancer cells. OXPHOS-IN-3 induces mitochondrial dysfunction, ferroptosis, and immunogenic cell death (ICD). OXPHOS-IN-3 shows potent antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models.
    OXPHOS-IN-3
  • HY-168011
    GPX4-IN-14
    		Activator
    GPX4-IN-14 (compound 2c) is an inhibitor of GPX4, with free radical scavenging activity (maximum scavenging rate is 72.52%) and anti-tumor proliferation activity in vitro. GPX4-IN-14 inhibits GPX4 protein, increases lipid peroxide levels and intracellular Reactive Oxygen Species (ROS) levels, thereby inducing ferroptosis and exerting anti-tumor proliferation effects.
    GPX4-IN-14
  • HY-174345
    Ferroptosis inducer-8
    		Inducer
    Ferroptosis inducer-8 is a ferroptosis inducer with high selectivity for other cell death mechanism. Ferroptosis inducer-8 induces ferroptosis by affecting ACSL4, GPX4, and FTH1, thereby disrupting intracellular iron homeostasis and the GSH/GPX4 antioxidant defense system, ultimately leading to the accumulation of lipid peroxidation. Ferroptosis inducer-8 also induces ROS production. Ferroptosis inducer-8 inhibits tumor growth and can be used for research of triple-negative breast cancer (TNBC).
    Ferroptosis inducer-8
  • HY-N0001S
    (±)-Epicatechin-13C3
    (±)-Epicatechin-13C3 is the 13C labeled (±)-Epicatechin. (-)-Epicatechin (HY-N0001) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.
    (±)-Epicatechin-<sup>13</sup>C<sub>3</sub>
  • HY-178389
    GPX4-IN-20
    		Inducer
    GPX4-IN-20, a Arctigenin (HY-N0035) derived, is a GPX4& molecular gluedegrader. GPX4-IN-20 induces ferroptosis by increasing lipid ROS levels and suppressing GSH levels. GPX4-IN-20 reduces the protein expression and enzyme activity of GPX4 in a dose-dependent manner without affecting other ferroptosis-related proteins. GPX4-IN-20 induces ubiquitination-dependent proteasomal degradation of GPX4. GPX4-IN-20 also increases the level of malondialdehyde (MDA) in HCT-116 cells. GPX4-IN-20 can be used for the research of colorectal cancer.
    GPX4-IN-20
  • HY-149723
    Ferroptosis-IN-5
    		Inhibitor
    Ferroptosis-IN-5 (compound 9c) is a ferroptosis inhibitor with iron-chelating and reactive oxygen species (ROS) scavenging activities.
    Ferroptosis-IN-5
  • HY-14164R
    Zileuton (Standard)
    		Inhibitor
    Zileuton (Standard) is the analytical standard of Zileuton. This product is intended for research and analytical applications. Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
    Zileuton (Standard)
  • HY-162716
    GPX4-IN-10
    		Inducer
    GPX4-IN-10 (compound I20) is a non-covalent GPX4 inhibitor. GPX4-IN-10 induces ferroptosis and inhibits cell growth of HT1080 cells.
    GPX4-IN-10
  • HY-178925
    PROTAC GPX4 degrader-5
    		Inducer
    PROTAC GPX4 degrader-5 (compound N15) is an efficient and highly selective PROTAC GPX4 degrader (DC50 = 28 nM). PROTAC GPX4 degrader-5 can induce ferroptosis and has low toxicity to normal cells. PROTAC GPX4 degrader-5 can significantly increase ROS. PROTAC GPX4 degrader-5 exerts anti proliferative effects on various tumor cells. PROTAC GPX4 degrader-5 is commonly used in cancer research.
    PROTAC GPX4 degrader-5
  • HY-161488
    Eugenol/BSA
    		Inhibitor
    Eugenol/BSA is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Eugenol/BSA
  • HY-105890
    Spiroplatin
    		Activator
    Spiroplatin is a Cisplatin (HY-17394) congener and has antitumor activity.
    Spiroplatin
  • HY-W020044S1
    DL-alpha-Tocopherol-d9
    DL-alpha-Tocopherol-d9 is the deuterium labeled DL-alpha-Tocopherol. DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB.
    DL-alpha-Tocopherol-d<sub>9</sub>
Cat. No. Product Name / Synonyms Application Reactivity
All Rights Reserved.
Download Ferroptosis Signaling Pathway Map.